We report a tick-borne case of severe Crimean-Congo haemorrhagic fever (CCHF) imported into Greece from Bulgaria. The patient presented severe thrombocytopenia, hemophagocytosis, haemodynamic instability, large haematomas and altered mental status. Supportive treatment and ribavirin were administered. Symptoms started one day after the tick was removed; the patient was discharged from the hospital 26 days after symptom onset. No secondary cases were observed. Phylogenetically the CCHF virus strain belongs to clade Europe 1.

In June 2018, Crimean-Congo haemorrhagic fever (CCHF) was diagnosed in a Greek construction worker who returned home after becoming ill with fever and haemorrhagic symptoms in south-western Bulgaria. Here, we describe the case along with the epidemiological investigation and phylogenetic analysis.

Case description
On 30 May 2018, a Greek male in his late 40s returned to Greece after spending 23 days in a forested area in Blagoevgrad province, south-western Bulgaria, where he was working in bridge construction. Three days earlier (27 May, day 1), while in Bulgaria, he developed fever, severe headache, myalgia (mainly in the lower extremities), malaise and loss of appetite; on 28 May he visited a local hospital and received symptomatic treatment as an outpatient. As his condition deteriorated (onset of photophobia and abdominal pain) he returned to his permanent residence in northern Greece. On 31 May (day 5), the patient was admitted to a local hospital. He was transferred to the university hospital in Alexandroupolis the next day because he presented severe thrombocytopenia and leukopenia; elevated levels of liver enzymes, creatine phosphokinase (CPK) and lactate dehydrogenase (LDH); and prolonged activated partial thromboplastin time (aPTT) (Table). On day 6, his headache was resolved but his fever (38.2 °C), malaise and myalgia were ongoing. The main laboratory findings were thrombocytopenia, prolonged aPTT (82 s) and increased level of aminotransferases. His laboratory parameters indicated rhabdomyolysis (CPK 1,739 U/L) and slightly elevated urea and creatinine levels (Table). A bone marrow biopsy showed haemophagocytosis.

On day 6, the first day after admittance to the hospital in Alexandroupolis, the patient was asked about any recent tick bites; he mentioned that on 26 May he had found and removed a tick from his abdomen (he had not reported it to the hospital in Bulgaria or the first hospital in Greece). Rickettsiosis was suspected and treatment with oral vibramycin (100 mg x 2) was started. One day later (day 7), he presented with a progressively extended haematoma on his left upper arm (bleeding from venipuncture sites) and on his lower back (Figure 1). The patient’s clinical condition deteriorated rapidly, and on day 8 he presented with an abrupt drop in haematocrit, further elevation of transaminases and low fibrinogen (< 100 mg/dl), haemodynamic instability and altered mental status (lethargy). The laboratory findings in serial samples can be seen in Table. An abdominal computed tomography scan showed retroperitoneal haematoma and extensive haematomas in muscle groups at the site of bone marrow biopsy.

Based on the patient’s clinical presentation, and as he was bitten by a tick in an area of Bulgaria where CCHF cases have been reported previously, CCHF was
highly suspected. Typically, the incubation period of CCHF after a tick bite is short (1–3 days), but the exact date of the bite was unknown in this case. The treating physician contacted the National Reference Centre for Arboviruses and Haemorrhagic Fever Viruses in Thessaloniki and the suspected case was immediately notified to the Hellenic Center for Disease Control and Prevention (HCDCP).

Laboratory diagnosis

Blood and serum samples taken from the case on day 9 of illness were sent to the National Reference Centre. CCHF was laboratory diagnosed by serology and PCR. CCHF virus (CCHFV) IgM antibodies were detected by ELISA (Vector Best, Novosibirsk, Russia); IgG antibodies were not detectable. Viral RNA was extracted from the blood sample using the QIamp viral RNA mini kit (Qiagen, Hilden, Germany). A real-time PCR (RT-PCR) (RealStar CCHFV RT-PCR Kit by Altona Diagnostics, Germany) resulted positive, with Ct-value 24.22. The viral load measured by an additional RT-PCR (method previously described in [1]) was 3.33 x 10^7 copies per ml of plasma, suggesting that it was still high on day 9 of illness. In order to obtain sequences, a nested RT-PCR that amplifies a partial fragment of the CCHFV S RNA segment was applied [2]. Additionally, a 1,440-bp fragment of the M RNA segment was amplified. The sequences of the S and M segments were aligned with respective sequences from the GenBank database using CLUSTAL W and phylogenetic analysis was performed using MEGA v.7 [3]. It was shown that the patient’s strain clustered in the CCHFV lineage Europe 1, together with other strains from the Balkan Peninsula (Figure 2).

Treatment and outcome

Upon admission to the second hospital in Greece, transfusion with fresh frozen plasma was initiated (3 units) and continued for 11 days (2–10 units daily). The patient was also transfused with concentrated red blood cells (2–4 units daily) and platelets (5–10 units daily). Following the laboratory confirmation of CCHF and although 10 days had passed from the onset of illness, oral ribavirin was initiated with a starting dose of 1 g (glomerular filtration rate = 40 ml/min), followed by 500 mg x 4 for 3 additional days. On day 14, the patient’s condition improved and laboratory parameters gradually returned to normal levels, at which time ribavirin was discontinued. The patient was discharged on day 26. One week later he was re-evaluated (clinically and laboratory) and found in good condition. A serum sample tested 1 month after discharge was positive for CCHFV IgG and IgM antibodies and negative for viral RNA.

### Table

Serial haematological and biochemical parameters in a Crimean-Congo haemorrhagic fever patient, Greece, June 2018

| Parameter (normal values) | Day of illness |
|---------------------------|---------------|
|                           | 5  | 6  | 7  | 9  | 10 | 12 | 14 | 15 | 17 | 19 | 22 | 24 |
| WBC (x 10⁹/L) (3.50–10.80) | 2.55 | 2.86 | 1.6 | 14.97 | 17.48 | 4.62 | 4.53 | 5.17 | 5.08 | 4.34 | 2.73 | 5.17 |
| Neutrophils (%) (40–75)    | 69  | 46.6 | 30  | 80.2 | 78.6 | 48.2 | 62  | 72.3 | 73.6 | 58.5 | 43.9 | 43.3 |
| Monocytes (%) (2–10)       | 1.2 | 5.2 | 10.6 | 5.6  | 10.2 | 19.9 | 14.8 | 12.6 | 9.1  | 9.7  | 11.4 | 6.6  |
| Basophiles (%) (0.3–1.0)   | 0   | 2.8 | 5   | 1.7  | 1.7  | 1.3  | 0.4  | 0.4  | 0.8  | 1.8  | 2.9  | 0.4  |
| Hematocrit (%) (35–45)     | 45.9 | 36.4 | 25.4 | 25.5 | 26.7 | 28.1 | 30.2 | 30.5 | 32.3 | 30.9 | 30.5 | 36.7 |
| Platelets (x 10⁹/L) (150–400) | 10  | 21 | 22  | 31  | 31  | 28  | 35  | 53  | 78  | 137 | 146 | 139  |
| aPTT (seconds) (25–37)     | 70.9 | NA  | NA  | 37.2 | 26.8 | 25.2 | 27.5 | 29  | 33.4 | 31.2 | 28  | 27.4 |
| Fibrinogen (mg/dl) (220–490) | 110.3 | NA  | NA  | 203 | 259 | 284 | 364 | 383 | 579 | 407 | 283 | 297  |
| Urea (mg/dl) (20–50)       | 65  | 76 | 95  | 108 | 108 | 102 | 94  | 73  | 95  | 105 | 67  | 31   |
| Creatinine (mg/dl) (0.6–1.1) | 2.1 | 1.8 | 1.9 | 2.2 | 2   | 1.5 | 1.6 | 1.5 | 1.4 | 1.4 | 1    |
| ALT (U/L) (≤ 33)           | 525 | 663 | 726 | 3,093 | 1,827 | 371 | 311 | 87  | 33  | 28  | 21  | 24   |
| ALP (U/L) (≤ 31)           | 116 | 150 | 166 | 870 | 638 | 257 | 144 | 92  | 52  | 38  | 36  | NA   |
| LDH (U/L) (120–246)        | 2,545 | 3,577 | 3,325 | 4,009 | 3,725 | 1,764 | 1,143 | 993 | 838 | 640 | 419 | 243  |
| CK (U/L) (55–170)          | 1,479 | 1,739 | 1,343 | 474 | 357 | 204 | 119 | 92  | 52  | 38  | 36  | NA   |
| Total bilirubin (mg/dl) (0.3–1.2) | NA  | NA  | 0.9 | 1.6 | 1.9 | 3.4 | 4.3 | 5.5 | 4   | 3.1 | 2   | 0.6  |
| Direct bilirubin (mg/dl) (≤ 0.2) | NA  | NA  | 0.4 | 0.9 | 0.8 | 1.1 | 1.5 | 1.4 | 1.1 | 0.8 | 0.2 |     |
| ALP (U/L) (30–120)         | 70  | 81 | 78  | 223 | 230 | 123 | 98  | 95  | 85  | 86  | 77  | 59   |
| γ-GT (mg/dl) (7–32)        | 26  | 45 | 68  | 189 | 171 | 122 | 105 | 109 | 101 | 106 | 79  | 28   |
| Serum amylase (U/L) (30–118) | NA  | NA  | 272 | 205 | 175 | 130 | 169 | 207 | 178 | 140 | NA | 67   |

ALP: alkaline phosphatase; ALT: alanine aminotransferase; aPTT: activated partial thromboplastin time; AST: aspartate aminotransferase; CK: creatine kinase; LDH: lactate dehydrogenase; NA: not available; WBC: white blood cells; γGT: gamma-glutamyltranspeptidase.
The HCDCP investigated the case immediately after the diagnosis of CCHF (through telephone interviews with a close family member and with the patient, after recovery, to confirm the dates) and his contacts while he was ill (household members, co-workers, roommates in Bulgaria and relatives who visited him in the hospitals). Close contacts were tested for CCHF and monitored for 14 days for any symptom development. The risk for further transmission was also assessed. The HCDCP promptly informed the Bulgarian health authorities about the case; they also informed the patient’s Greek co-workers in Bulgaria about preventive measures and proper management of tick bites (informative material in Greek was sent to them) advising them to seek medical care in case they develop symptoms. No other cases were reported among the patient’s co-workers in Bulgaria, up to the end of July 2018.

The HCDCP sent guidelines for contact tracing and active surveillance of symptoms in HCWs possibly exposed to CCHFV. Patients who were hospitalised in the same room with the patient before the suspicion of CCHF (two patients in the first hospital (days 5–6), and three patients in the second hospital (days 6–8)) were also monitored for symptoms for 14 days after their last contact with the patient. No secondary cases were observed.

Infection control

The patient and his laboratory samples, apparel, waste and cleaning procedures were managed in accordance with the national guidelines for viral haemorrhagic fevers (available in Greek from HCDCP website: http://www.keelpno.gr/). In particular, upon the suspicion of CCHF (day 8) the patient was immediately isolated and strict barrier precautions were utilised (waterproof gowns, gloves, FFP3 respiratory masks, goggles), and personal protective equipment was used by healthcare workers (HCWs) and visitors; however, visitors were discouraged from entering the isolation room. The HCDCP sent guidelines for contact tracing and active surveillance of symptoms in HCWs possibly exposed to CCHFV. Patients who were hospitalised in the same room with the patient before the suspicion of CCHF (two patients in the first hospital (days 5–6), and three patients in the second hospital (days 6–8)) were also monitored for symptoms for 14 days after their last contact with the patient. No secondary cases were observed.

Discussion

Crimean-Congo haemorrhagic fever (genus Orthohantavirus, family Nairoviridae) circulates in nature in an enzootic cycle between ticks and non-human vertebrates. It is transmitted to humans by bite of infected Ixodid ticks (mainly Hyalomma spp.) or by contact with blood or tissues of viraemic patients or animals [4]. Nosocomial infections are often reported. Here we report a CCHF case imported into Greece from south-western Bulgaria, where the patient was working on a construction site. He presented with the first symptoms 1 day after the removal of a tick from his abdomen.

CCHF was first recognised in Bulgaria in 1952; since then, several cases have been reported. Genetic characterisation of the Bulgarian strains showed that they cluster into the clade Europe 1 [5]. Our patient was infected in an area that was considered at low risk for CCHF outbreaks up to 2008, when a cluster of cases was observed in the region [6]. Although the seroprevalence in the human population in Blagoevgrad province is low (1%) [5], a seroprevalence of 41.9% in livestock was reported recently [7]. Since CCHFV is transmitted mainly by bite of infected Ixodid ticks, persons living in rural areas are at increased risk for acquiring the infection. This was the reason that information about preventive measures was sent to our patient’s Greek co-workers in Bulgaria, and all related public health authorities were informed about the case.
Figure 2
Maximum likelihood phylogenetic trees based on (A) 202-bp fragment of Crimean-Congo haemorrhagic fever virus S RNA segment and (B) 1,440-bp fragment of Crimean-Congo haemorrhagic fever virus M RNA segment, Greece, 2018

A. Maximum likelihood phylogenetic tree based on 202-bp fragment of Crimean-Congo haemorrhagic fever virus S RNA segment

B. Maximum likelihood phylogenetic tree based on 1,440-bp fragment of Crimean-Congo haemorrhagic fever virus M RNA segment

The Kimura 2-parameter model was applied. The trees are drawn to scale, with branch lengths measured in the number of substitutions per site. The percentage of replicate trees in which the associated taxa clustered together in the bootstrap test (1,000 replicates) is shown next to the branches. Bootstrap values lower than 60% are not shown. Sequences in the trees are indicated as GenBank accession number and country of isolation. Sequences of the present study are marked.
Regarding Greece, no other imported cases have been reported so far and the only autochthonous CCHF case was observed in 2008 [8]. A review of travel-associated CCHF cases published during 1960–2016 reported 21 cases [9]; two imported cases have been reported within Europe: Bulgaria to Germany in 2001 [10] and Bulgaria to the United Kingdom in 2014 [11].

Due to the high pathogenicity of the CCHFV, the absence of a specific drug treatment or vaccine and the risk of person-to-person transmission, rapid diagnosis is crucial to ensure that appropriate infection control measures (e.g. isolation of patient and barrier precautions) can be implemented in a timely manner. A detailed medical history of the patient, including travel history and possible risk factors, is important for the timely diagnosis of the disease. In our case, information regarding the tick bite was not provided immediately and this, in combination with the non-specific initial symptoms, meant that CCHF was first suspected on day 8 of illness. Despite this delay, the patient fully recovered and no secondary cases of CCHF have been reported. Since the northern part of Greece is close to CCHF-endemic countries, HCWs in this region should be made aware of CCHF; including the provision of training to better help them address questions from patients about travel history (identify potential risk of exposure). Physicians should include CCHF in the differential diagnosis for patients with haemorrhagic syndromes, especially if patients report a tick bite, outdoor activities or occupation in rural areas and recent travel to an endemic area.

Acknowledgements
The study was financially supported by the Hellenic Centre for Disease Control and Prevention and the EU Horizon 2020 research and innovation programme COMPARE (grant agreement No 643476). The National Reference Centre for Arboviruses and Haemorrhagic Fever viruses participates in the EMERGE project Joint Action (CHAFEA n° 677 066).

We thank the patient for providing consent for the publication. We would like to acknowledge all health-care professionals from local hospitals, the regional and local public health authorities and Anmita Vakali, from the Vector-borne Disease Office of the HCDCP, for their support in case and contacts investigation and management. We thank Elpida Gavana for the serology testing.

Conflict of interest
None declared.

Authors’ contributions
AP undertook the data analysis, directed and evaluated the laboratory diagnosis, performed the phylogenetic analysis and drafted the manuscript. ET performed the clinical diagnosis. FM and EM clinically managed the patient and provided detailed case information. The photo of the patient was provided by EM. HM performed the infection control. DP performed the epidemiological investigation. SV took care of the patient and of the infection control and provided data. ST gave the initial instructions for the case management. EP performed the molecular analysis. All authors reviewed and approved the final version of the manuscript.

References
1. Papa A, Drosten C, Bino S, Papadimitriou E, Panning M, Velo E, et al. Viral load and Crimean-Congo hemorrhagic fever. Emerg Infect Dis. 2007;13(5):805-6. https://doi.org/10.3201/eid1305.060588 PMID: 18044055
2. Schwarz TF, Nsanze H, Longson M, Nitschko H, Gilch S, Shurie H, et al. Polymerase chain reaction for diagnosis and identification of distinct variants of Crimean-Congo hemorrhagic fever virus in ruminants in the absence of reported human cases in many regions of Bulgaria. Exp Appl Acarol. 2019;110(2):227-34. https://doi.org/10.1007/s10493-018-0258-7 PMID: 29731938
3. Papa A, Maltezou HC, Tsiodras S, Dalla VG, Papadimitriou T, Pierroutsakos I, et al. A case of Crimean-Congo haemorrhagic fever in Greece, June 2008. Euro Surveill. 2008;13(33):18952. https://doi.org/10.2807/ese.13.33.18952-en PMID: 18761893
4. Papa A, Maltezou HC, Trifonov M, Tchakarova S, Sas MA. High seroprevalence for Crimean-Congo haemorrhagic fever virus in ruminants of southwestern Bulgaria. Emerg Infect Dis. 2009;15(6):983-5. https://doi.org/10.3201/eid1506.081567 PMID: 19523314
5. Christova I, Di Caro A, Papa A, Castilletti C, Andonova L, Kalvatchev N, et al. Crimean-Congo hemorrhagic fever, southwestern Bulgaria. Emerg Infect Dis. 2009;15(6):983-5. https://doi.org/10.3201/eid1506.081567 PMID: 19523314
6. Christova I, Panayotova E, Groschup MH, Trifonov I, Tchakarova S, Sas MA. High seroprevalence for Crimean-Congo hemorrhagic fever virus in ruminants in the absence of reported human cases in many regions of Bulgaria. Exp Appl Acarol. 2019;110(2):227-34. https://doi.org/10.1007/s10493-018-0258-7 PMID: 29731938
7. Papa A, Maltezou HC, Tsiodras S, Dalla VG, Papadimitriou T, Pierroutsakos I, et al. A case of Crimean-Congo haemorrhagic fever in Greece, June 2008. Euro Surveill. 2008;13(33):18952. https://doi.org/10.2807/ese.13.33.18952-en PMID: 18761893
8. Papa A, Maltezou HC, Tsiodras S, Dalla VG, Papadimitriou T, Pierroutsakos I, et al. A case of Crimean-Congo haemorrhagic fever in Greece, June 2008. Euro Surveill. 2008;13(33):18952. https://doi.org/10.2807/ese.13.33.18952-en PMID: 18761893
9. Leblecioglu H, Ozaras R, Fletcher TE, Beeching NJ. ESCMID Study Group for Infections in Travellers and Migrants (ESGITM). Crimean-Congo hemorrhagic fever in travellers: A systematic review. Travel Med Infect Dis. 2016;14(2):73-80. https://doi.org/10.1016/j.tmaid.2016.03.002 PMID: 26970396
10. European Centre for Disease Prevention and Control (ECDC). Meeting report. Consultation on Crimean-Congo hemorrhagic fever prevention and control. Stockholm: ECDC; 2008. Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/0809_MER_Crimean_Congo_Haemorrhagic_Fever_Prevention_and_Control.pdf
11. Lumley S, Atkinson B, Dowall S, Pitman J, Staplehurst S, Pierroutsakos I, et al. Viral load and Crimean-Congo hemorrhagic fever. Exp Appl Acarol. 2018;75(2):227-34. https://doi.org/10.1007/s10493-018-06158-8 PMID: 29731938

License and copyright
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.

This article is copyright of the authors or their affiliated institutions, 2018.